Literature DB >> 11494123

Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions.

M Jaumot1, J F Hancock.   

Abstract

Raf-1 activation is a complex process which involves plasma membrane recruitment, phosphorylation, protein-protein and lipid-protein interactions. We now show that PP1 and PP2A serine-threonine phosphatases also have a positive role in Ras dependent Raf-1 activation. General serine-threonine phosphatase inhibitors such sodium fluoride, or ss-glycerophosphate and sodium pyrophosphate, or specific PP1 and PP2A inhibitors including microcystin-LR, protein phosphatase 2A inhibitor I(1) or protein phosphatase inhibitor 2 all abrogate H-Ras and K-Ras dependent Raf-1 activation in vitro. A critical Raf-1 target residue for PP1 and PP2A is S259. Serine phosphatase inhibitors block the dephosphorylation of S259, which accompanies Raf-1 activation, and Ras dependent activation of mutant Raf259A is relatively resistant to serine phosphatase inhibitors. Sucrose gradient analysis demonstrates that serine phosphatase inhibition increases the total amount of 14-3-3 and Raf-1 associated with the plasma membrane and significantly alters the distribution of 14-3-3 and Raf-1 across different plasma membrane microdomains. These observations suggest that dephosphorylation of S259 is a critical early step in Ras dependent Raf-1 activation which facilitates 14-3-3 displacement. Inhibition of PP1 and PP2A therefore causes plasma membrane accumulation of Raf-1/14-3-3 complexes which cannot be activated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494123     DOI: 10.1038/sj.onc.1204526

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  65 in total

1.  14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity.

Authors:  Yvonne Light; Hugh Paterson; Richard Marais
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

Review 2.  Mechanistic principles of RAF kinase signaling.

Authors:  Christian M Udell; Thanashan Rajakulendran; Frank Sicheri; Marc Therrien
Journal:  Cell Mol Life Sci       Date:  2010-09-06       Impact factor: 9.261

3.  KSR1 modulates the sensitivity of mitogen-activated protein kinase pathway activation in T cells without altering fundamental system outputs.

Authors:  Joseph Lin; Angus Harding; Emanuele Giurisato; Andrey S Shaw
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

4.  Ras binding opens c-Raf to expose the docking site for mitogen-activated protein kinase kinase.

Authors:  Kenta Terai; Michiyuki Matsuda
Journal:  EMBO Rep       Date:  2005-03       Impact factor: 8.807

5.  Palmitoylation of oncogenic NRAS is essential for leukemogenesis.

Authors:  Benjamin Cuiffo; Ruibao Ren
Journal:  Blood       Date:  2010-03-03       Impact factor: 22.113

Review 6.  Regulation of RAF protein kinases in ERK signalling.

Authors:  Hugo Lavoie; Marc Therrien
Journal:  Nat Rev Mol Cell Biol       Date:  2015-05       Impact factor: 94.444

7.  Improved immunohistochemical detection of phosphorylated mitogen-activated protein kinases in the injured rat optic nerve head.

Authors:  Teresa Mammone; Glyn Chidlow; Robert J Casson; John P M Wood
Journal:  Histochem Cell Biol       Date:  2019-03-11       Impact factor: 4.304

8.  Modulation of KSR activity in Caenorhabditis elegans by Zn ions, PAR-1 kinase and PP2A phosphatase.

Authors:  John H Yoder; Huira Chong; Kun-Liang Guan; Min Han
Journal:  EMBO J       Date:  2003-12-11       Impact factor: 11.598

9.  Small G proteins exhibit pattern sensitivity in MAPK activation during the induction of memory and synaptic facilitation in Aplysia.

Authors:  Xiaojing Ye; Justin L Shobe; Shiv K Sharma; Andreea Marina; Thomas J Carew
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

10.  Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms.

Authors:  Isabelle Hmitou; Sabine Druillennec; Agathe Valluet; Carole Peyssonnaux; Alain Eychène
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.